Dr. Patrick A. Flume, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at San Antonio (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 189
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Texas Medical School at San Antonio
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
SC license 16591
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Musc Medical Center Charleston, SC
- Tidelands Waccamaw Community Hospital Murrells Inlet, SC
- Musc Health Columbia Medical Center Downtown Columbia, SC
- Beaufort County Memorial Hospital Beaufort, SC
Medical groups
- University Medical Associates of the Medical University of South Carol (1,668 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 189
- Services billed
- 268
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 119 | 101 |
| Established patient office or other outpatient visit, 30-39 minutes | 117 | 94 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azithromycin Other prescribers in Charleston, SC | 128 |
| Trikafta (elexacaftor/tezacaftor/ivacaft) | 93 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Charleston, SC | 84 |
| Ethambutol Hcl | 63 |
| Creon (lipase/protease/amylase) Other prescribers in Charleston, SC | 56 |
| Nuzyra (omadacycline tosylate) | 45 |
| Amikacin Sulfate | 43 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Charleston, SC | 42 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Charleston, SC | 35 |
| Prednisone Other prescribers in Charleston, SC | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 41 payments worth $73,453 in total to this clinician.
| Insmed, Inc. | $26,692 |
|---|---|
| Vertex Pharmaceuticals Incorporated | $26,597 |
| Paratek Pharmaceuticals, Inc. | $9,235 |
| Boehringer Ingelheim International GmbH | $8,005 |
| Mannkind Corporation | $2,925 |
| Consulting Fee | $41,947 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $23,775 |
| Travel and Lodging | $6,811 |
| Food and Beverage | $920 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $13,726 |
| Insmed, Inc. Dec 5, 2025 | Consulting Fee Arikayce · Respiratory | $11,552 |
| Paratek Pharmaceuticals, Inc. May 13, 2025 | Consulting Fee NUZYRA · ANTIBIOTIC | $8,190 |
| Vertex Pharmaceuticals Incorporated Apr 4, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,560 |
| Vertex Pharmaceuticals Incorporated Oct 15, 2025 | Travel and Lodging travel to LONDON, Great Britain (UK) · in-kind | $4,446 |
| Insmed, Inc. Sep 19, 2025 | Consulting Fee | $3,610 |
| Boehringer Ingelheim International GmbH Jun 2, 2025 | Consulting Fee | $3,395 |
| Mannkind Corporation Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,925 |
| Boehringer Ingelheim International GmbH Sep 26, 2025 | Consulting Fee | $2,245 |
| Insmed, Inc. May 29, 2025 | Consulting Fee | $2,166 |
All 27 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $13,726 |
| Insmed, Inc. Dec 5, 2025 | Consulting Fee Arikayce · Respiratory | $11,552 |
| Insmed, Inc. Nov 12, 2025 | Travel and Lodging Arikayce · Respiratory · travel to Portland, OR · in-kind | $302 |
| Boehringer Ingelheim International GmbH Oct 25, 2025 | Consulting Fee | $2,100 |
| Vertex Pharmaceuticals Incorporated Oct 19, 2025 | Travel and Lodging travel to LONDON, Great Britain (UK) · in-kind | $348 |
| Vertex Pharmaceuticals Incorporated Oct 19, 2025 | Travel and Lodging travel to LONDON, Great Britain (UK) · in-kind | $348 |
| Vertex Pharmaceuticals Incorporated Oct 19, 2025 | Travel and Lodging travel to LONDON, Great Britain (UK) · in-kind | $348 |
| Vertex Pharmaceuticals Incorporated Oct 15, 2025 | Travel and Lodging travel to LONDON, Great Britain (UK) · in-kind | $4,446 |
| Insmed, Inc. Oct 9, 2025 | Travel and Lodging Arikayce · Respiratory · travel to Portland, OR · in-kind | $187 |
| Insmed, Inc. Oct 9, 2025 | Travel and Lodging Arikayce · Respiratory · travel to Portland, OR · in-kind | $187 |
| Boehringer Ingelheim International GmbH Sep 26, 2025 | Consulting Fee | $2,245 |
| Insmed, Inc. Sep 19, 2025 | Consulting Fee | $3,610 |
| Mannkind Corporation Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,925 |
| Vertex Pharmaceuticals Incorporated Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,564 |
| Insmed, Inc. Jun 13, 2025 | Consulting Fee | $1,444 |
| Boehringer Ingelheim International GmbH Jun 2, 2025 | Consulting Fee | $3,395 |
| Insmed, Inc. May 29, 2025 | Consulting Fee | $2,166 |
| Paratek Pharmaceuticals, Inc. May 13, 2025 | Consulting Fee NUZYRA · ANTIBIOTIC | $8,190 |
| Paratek Pharmaceuticals, Inc. May 13, 2025 | Travel and Lodging NUZYRA · ANTIBIOTIC · travel to DENVER, CO | $358 |
| Insmed, Inc. May 9, 2025 | Consulting Fee | $1,083 |
| Insmed, Inc. May 9, 2025 | Consulting Fee Arikayce · Respiratory | $722 |
| Insmed, Inc. Apr 16, 2025 | Consulting Fee Arikayce · Respiratory | $722 |
| Paratek Pharmaceuticals, Inc. Apr 7, 2025 | Travel and Lodging NUZYRA · ANTIBIOTIC · travel to DENVER, CO · in-kind | $288 |
| Vertex Pharmaceuticals Incorporated Apr 4, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,560 |
| Insmed, Inc. Mar 5, 2025 | Consulting Fee Arikayce · Respiratory | $1,444 |
| Insmed, Inc. Feb 28, 2025 | Consulting Fee | $1,830 |
| Insmed, Inc. Jan 23, 2025 | Consulting Fee Arikayce · Respiratory | $1,444 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 7 companies. The companies reported $258,964 in research payments for these studies, mostly to the institutions running them.
- Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Paratek Pharmaceuticals, Inc. · Completed · NCT04922554 - A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy
Vertex Pharmaceuticals Incorporated - A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Sanofi US Services Inc. · Completed · NCT06280391 - A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)
Boehringer Ingelheim Pharmaceuticals, Inc. - ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Mannkind Corporation · Terminated · NCT06418711 - Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Insmed, Inc. · Completed · NCT04677569 - A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.